Comparative Pharmacology
Head-to-head clinical analysis: TYVASO versus TYVASO DPI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TYVASO versus TYVASO DPI.
TYVASO vs TYVASO DPI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial beds and inhibits platelet aggregation. It binds to IP receptors, increasing cAMP in smooth muscle cells, leading to vasodilation.
Treprostinil is a prostacyclin analog that directly causes vasodilation of pulmonary and systemic arterial vascular beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.
Inhalation solution: 0.6 mg/mL, 1.74 mg/2.9 mL via the Tyvaso Inhalation System. Administer 3 breaths (approximately 72 mcg per breath) per treatment session, 4 times daily, with at least 4 hours between doses. May increase to 9 breaths per session if tolerated. Maximum dose: 9 breaths (approximately 216 mcg) 4 times daily.
Inhalation powder: 16 mcg (1 capsule) via Tyvaso DPI inhaler four times daily (QID) with approximately 4-hour intervals during waking hours. Titrate as tolerated to target dose of 64 mcg (4 capsules) QID.
None Documented
None Documented
The terminal elimination half-life of treprostinil (Tyvaso) is approximately 4 hours following inhalation and 4.5 hours after subcutaneous administration. This half-life supports a four-times-daily dosing regimen for the inhaled formulation to maintain therapeutic plasma concentrations.
Terminal half-life: 1.4-2.0 hours; clinical context: supports continuous dosing for sustained pulmonary arterial hypertension effect.
Treprostinil is primarily eliminated via hepatic metabolism; urinary excretion of unchanged drug is negligible (approximately 4%). Biliary/fecal excretion accounts for the majority of elimination (around 70% as metabolites).
Renal: 6-9% as unchanged treprostinil; biliary/fecal: ~70% as metabolites; total clearance: 20-40 L/h.
Category C
Category C
Pulmonary Arterial Hypertension Agent
Pulmonary Arterial Hypertension Agent